Short Interest in Oculis Holding AG Surges 63.9%

Oculis stock sees significant increase in shares sold short over the past month.

Mar. 13, 2026 at 10:09pm

Got story updates? Submit your updates here. ›

Oculis Holding AG (NASDAQ:OCS), a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies, saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 623,971 shares, an increase of 63.9% from the February 12th total of 380,803 shares. Approximately 1.1% of the company's shares are currently sold short.

Why it matters

The rise in short interest could indicate increased bearish sentiment among investors regarding Oculis' stock performance or future prospects. Short selling activity can influence a stock's price movements and trading volume, potentially signaling market uncertainty or skepticism about the company's outlook.

The details

Based on an average trading volume of 277,382 shares, the short-interest ratio is currently 2.2 days, meaning it would take short sellers about 2 days to cover their positions at the current volume. The increase in short interest comes as Oculis' stock price has fluctuated in recent months, with the share price reaching a 52-week high of $30.68 in early March.

  • As of February 27th, 2026, there was short interest totaling 623,971 shares.
  • This represents a 63.9% increase from the February 12th, 2026 total of 380,803 shares.

The players

Oculis Holding AG

A clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies.

Got photos? Submit your photos here. ›

The takeaway

The surge in short interest in Oculis' stock could signal growing investor skepticism about the company's future performance and prospects, though the reasons behind the increased short selling activity are not entirely clear. Analysts will likely continue to monitor Oculis' stock movements and short interest levels for any further developments.